

# HOLD TP: Rs 595 | A 4%

GREENPANEL INDUSTRIES

Construction Materials

06 May 2022

Ruchitaa Maheshwari

researchreport@bobcaps.in

Strong margin expansion despite lower MDF & plywood volumes

- Q4 revenue climbed 21% YoY to Rs 4.7bn led by 31% growth in MDF but plywood revenue declined by 15%
- Gross margin stood at 61.5% vs. 54.1% in the year-ago quarter; EBITDA margin expanded 470bps YoY to 29.3%
- Maintain HOLD with an unchanged TP of Rs 595; recommend using any weakness in the stock as an entry-point

**Strong growth aided by higher MDF realisations:** GREENP's consolidated Q4FY22 revenue grew 21% YoY to Rs 4.7bn, with MDF up 31% as blended realisations increased 44% YoY and 8% QoQ. However, plywood revenue declined 15% YoY. EBITDA margin stood at 29.3% vs. 24.6% in the year-ago quarter due to a superior product mix, cost optimisation and operating leverage.

**Lower MDF volumes but EBITDA margin expands:** MDF volumes declined by 11% YoY due to the recurrence of Covid, state elections and higher inflation. Nevertheless, segmental EBITDA margin improved 600bps YoY to 34.6% on the strength of higher realisations and a superior product mix. For FY22, MDF margins stood at 31% vs. 23% in FY21. Management has guided for ~31% levels in FY23.

**Plywood margin declines:** Plywood earned a lower Q4 EBITDA margin at 9.2% (-630bps YoY) due to higher raw material cost and a 19% fall in volumes. Management indicated plans for a price hike in Q1FY23 and has guided for a 10-11% segmental EBITDA margin for FY23.

**MDF volume growth guided at 15-18% in FY23E:** Management expects MDF volume growth of 15-18% in FY23 vs. 30% in FY22. The company looks poised to capitalise on the near-term steady growth from rising acceptance of MDF in the readymade furniture market and the absence of major capacity additions in the industry during FY23 (beyond Rushil Décor's 240,000cbm expansion which has already been absorbed and CPBI's upcoming 130,000cbm addition in H1FY23).

**Maintain HOLD:** GREENP has strong growth prospects due to its leadership position in India's fast-growing MDF market coupled with an improving balance sheet and return ratios. With growth momentum likely to continue and the absence of significant capex, we expect the company to turn net debt-free in FY23. The stock is trading at 22.1x FY24E EPS and has achieved our TP of Rs 595 on 23 Mar 2022. We continue to value GREENP at 23x FY24E EPS (a 33% discount to CPBI) and retain our TP of Rs 595 with a HOLD rating. In our view, any weakness in the stock should be used as an opportunity to enter.

Key changes

	Target	Rating	
	<►	<►	
Ticker/F	Price	GREENP IN/Rs 571	
Market	сар	US\$ 910.1mn	
Free flo	at	47%	
3M AD	/	US\$ 2.5mn	
52wk hi	gh/low	Rs 626/Rs 215	
Promote	er/FPI/DII	53%/6%/41%	
-			

Source: NSE | Price as of 6 May 2022

### Key financials

Y/E 31 Mar	FY22P	FY23E	FY24E
Total revenue (Rs mn)	16,250	18,350	20,545
EBITDA (Rs mn)	4,304	4,685	5,302
Adj. net profit (Rs mn)	2,405	2,662	3,171
Adj. EPS (Rs)	19.6	21.7	25.9
Consensus EPS (Rs)	19.6	22.3	25.6
Adj. ROAE (%)	28.6	25.5	25.4
Adj. P/E (x)	29.1	26.3	22.1
EV/EBITDA (x)	17.3	15.4	13.2
Adj. EPS growth (%)	197.6	10.7	19.1

Source: Company, Bloomberg, BOBCAPS Research | P - Provisional

### Stock performance



Source: NSE





# Earnings call highlights

- MDF exports and guidance for FY23: Management expects MDF exports to remain high at 120,000-125,000cbm in FY23. Further, if domestic demand slows down, export volumes will rise further. GREENP exports to the Middle East, South East Asia, the UK and Korea, among others. It is also receiving enquiries from Germany.
- Lower imports eased pressure on domestic MDF prices: MDF imports have reduced and currently pose no threat to domestic players due to (a) price inflation in international MDF, (b) higher ocean freight cost, and (c) increased domestic consumption of the product in the key exporting countries of Vietnam and Indonesia.
- OEM exposure has reduced considerably: The company has considerably reduced its exposure to OEMs from 30-32% of domestic MDF revenue a year ago to 15-16% currently. This has further helped in improving MDF margins in Q4FY22.
- **Capex plan for FY23:** The capex plan will be finalised in May/Jun'22 for the planned MDF capacity expansion in Andhra Pradesh.
- MDF capacity in India: India's MDF capacity has risen from 1.9mn cbm in FY21 (demand: 1.5mn cbm) to 2.3mn cbm currently (demand: 1.7-1.8mn cbm). Capacity is expected to rise to 3mn cbm by FY25, with demand of ~2.5mn cbm.
- Others result highlights: (1) MDF accounted for 85% of revenue in Q4FY22 vs. 78% in Q4FY21. (2) Working capital cycle reduced by 19 days YoY to 16 days as on Mar'22. (3) Net debt reduced by Rs 840mn to Rs 0.6bn. Management aims to be net debt-free by Jun'22. (4) Value-added products contributed 13% of revenue in Q4FY22 vs. 11% in Q4FY21. (5) The term loan from LBBW has been prepaid to the extent of EUR 9mn in FY22 which substantially brought down the company's debt and foreign currency exposure.

Fig 1 – Consolidated quarterly performance

(Rs mn)	Q4FY22	Q4FY21	YoY (%)	Q3FY22	QoQ (%)	FY22	FY21	YoY (%)
Net Revenue	4,701	3,888	20.9	4,244	10.8	16,250	10,208	59.2
COGS	1,827	1,783	2.5	1,794	1.8	6,709	4,629	44.9
% of sales	38.9	45.9	(700bps)	42.3	(341bps)	41.3	45.3	(406bps)
Employee expenses	353	292	21.1	330	7.1	1,284	979	31.2
% of sales	7.5	7.5	1bps	7.8	(26bps)	7.9	9.6	(169bps)
Operating Expenses	1,143	856	33.5	1,010	13.2	3,953	2,566	54.0
% of sales	24.3	22.0	229bps	23.8	52bps	24.3	25.1	(82bps)
EBITDA	1,378	957	44.0	1,111	24.1	4,304	2,034	111.7
EBITDA Margin (%)	29.3	24.6	470bps	26.2	314bps	26.5	19.9	656bps
Depreciation/Amortisation	183	170	7.8	184	(0.6)	734	686	6.9
EBIT	1,195	787	51.8	927	29.0	3,571	1,347	165.0
EBIT Margin (%)	25.4	20.2	518bps	21.8	359bps	22.0	13.2	877bps
Net Interest Expenses	34	41	(17.7)	13	154.8	171	247	(30.8)
Other Income	37	20	83.6	23	61.1	90	34	159.9
PBT	1,198	766	56.4	936	28.0	3,489	1,135	207.5
Tax Expenses	392	292	34.2	305	28.4	1,085	322	237.3
Reported PAT	806	474	70.1	631	27.8	2,405	813	195.8

Source: Company, BOBCAPS Research


### Fig 2 – Consolidated segmental performance

(Rs mn)	Q4FY22	Q4FY21	YoY (%)	Q3FY22	QoQ (%)	FY22	FY21	YoY (%)
Revenue								
Plywood & Allied products	706	828	(14.8)	671	5.2	2,562	2,174	17.9
MDF & Allied products	3,995	3,060	30.6	3,573	11.8	13,688	8,034	70.4
Total	4,701	3,888	20.9	4,244	10.8	16,250	10,208	59.2
Less: Inter Segment revenue	0	0	n.m.	0	n.m.	0	0	n.m.
Net revenues	4,701	3,888	20.9	4,244	10.8	16,250	10,208	59.2
EBIT								
Plywood & Allied products	79	142	(44.5)	80	(1.3)	325	297	9.5
MDF & Allied products	1,314	808	62.6	1,033	27.2	3,922	1,483	164.5
Total	1,393	950	46.7	1,113	25.1	4,247	1,780	138.6
EBIT Margin (%)								
Plywood & Allied products	11.1	17.1	(595bps)	11.9	(74bps)	12.7	13.6	(96bps)
MDF & Allied products	32.9	26.4	648bps	28.9	398bps	28.7	18.5	1,019bps
Denne								

Source: Company, BOBCAPS Research








### Fig 3 – Consolidated revenue growth


Source: Company, BOBCAPS Research






Source: Company, BOBCAPS Research

#### Fig 7 – MDF revenue



Source: Company, BOBCAPS Research

### Fig 4 – Consolidated EBITDA margin



Source: Company, BOBCAPS Research

#### - Growth YoY (R) (%) MDF realisation (msm) 29,025 31,300 35,000 30,000 24,446 20,030 20,138 21,730 22,528 25,000 18,908 20,000 15,000 19 10,000 10 5,000 1.3

Q4FY21

Q3FY21

Q1FY22

Q2FY22

# Fig 6 – MDF realization




FY21

0

### Fig 8 – MDF EBITDA margin

**Q2FY21** 



Source: Company, BOBCAPS Research

50

40

30

20

10

0


Q3FY22

Q4FY22

(10)




### Fig 9 – Plywood revenue



Source: Company, BOBCAPS Research

### Fig 10 – Plywood EBITDA margin



Source: Company, BOBCAPS Research



# Valuation methodology

GREENP has strong growth prospects due to its leadership position in India's fastgrowing MDF market coupled with an improving balance sheet and return ratios. We model for a revenue/EBITDA/PAT CAGR of 26%/37%/58% over FY21-FY24 aided by better capacity utilisation at the MDF facility and a higher EBITDA margin arising from operating leverage. With growth momentum likely to continue and the absence of significant capex, we expect the company to turn net debt-free in FY23.

GREENP is trading at 22.1x FY24E EPS and has achieved our TP of Rs 595 on 23 Mar 2022. We continue to value the stock at 23x FY24E EPS (a 33% discount to CPBI) and retain our TP of Rs 595 with a HOLD rating. In our view, any weakness in the stock should be used as an opportunity to enter.

FY21	FY22	FY23E	FY24E
380,430	495,041	570,000	660,000
20.4	30.1	15.1	15.8
7,840	13,292	15,102	16,873
27.8	69.5	13.6	11.7
20.9	27.3	27.7	28.1
8.5	9.3	12.1	13.7
(0.4)	9.7	29.8	13.0
2,016	2,559	3,248	3,672
1.6	17.9	26.9	13.0
13.6	14.9	15.2	15.3
	380,430 20.4 7,840 27.8 20.9 8.5 (0.4) 2,016 1.6	380,430         495,041           20.4         30.1           7,840         13,292           27.8         69.5           20.9         27.3           8.5         9.3           (0.4)         9.7           2,016         2,559           1.6         17.9	380,430         495,041         570,000           20.4         30.1         15.1           7,840         13,292         15,102           27.8         69.5         13.6           20.9         27.3         27.7           8.5         9.3         12.1           (0.4)         9.7         29.8           2,016         2,559         3,248           1.6         17.9         26.9

Fig 11 – Key assumptions

Source: Company, BOBCAPS Research

### **Key risks**

Key upside risks to our estimates are:

- consolidation of the informal sector where weaker players exit from the market,
- fast revival in economy and in housing demand,
- significant pickup in MDF exports,
- steep uptick in MDF margins and export realisations, and
- sharp decline in chemical and wood costs.

### Sector recommendation snapshot

Ticker	Market Cap (US\$ bn)	Price (Rs)	Target (Rs)	Rating
CPBI IN	1.7	580	735	HOLD
CRS IN	0.7	3,958	5,590	BUY
GREENP IN	0.9	571	595	HOLD
MTLM IN	0.3	203	260	BUY
KJC IN	2.1	1,023	1,460	BUY
PIDI IN	14.8	2,237	2,445	HOLD
SOMC IN	0.4	638	1,140	BUY
	CPBI IN CRS IN GREENP IN MTLM IN KJC IN PIDI IN	CPBI IN         1.7           CRS IN         0.7           GREENP IN         0.9           MTLM IN         0.3           KJC IN         2.1           PIDI IN         14.8	CPBI IN         1.7         580           CRS IN         0.7         3,958           GREENP IN         0.9         571           MTLM IN         0.3         203           KJC IN         2.1         1,023           PIDI IN         14.8         2,237	CPBI IN         1.7         580         735           CRS IN         0.7         3,958         5,590           GREENP IN         0.9         571         595           MTLM IN         0.3         203         260           KJC IN         2.1         1,023         1,460           PIDI IN         14.8         2,237         2,445

Source: BOBCAPS Research, NSE | Price as of 6 May 2022



# Financials

Income Statement					
Y/E 31 Mar (Rs mn)	FY20A	FY21A	FY22P	FY23E	FY24E
Total revenue	8,766	10,208	16,250	18,350	20,545
EBITDA	1,432	2,077	4,304	4,685	5,302
Depreciation	(692)	(686)	(734)	(754)	(771)
EBIT	740	1,391	3,571	3,931	4,531
Net interest inc./(exp.)	(302)	(247)	(171)	(180)	(90)
Other inc./(exp.)	22	31	90	52	89
Exceptional items	(343)	(165)	0	0	0
EBT	460	1,175	3,489	3,803	4,530
Income taxes	28	(322)	(1,085)	(1,141)	(1,359)
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	0	0	0	0	0
Reported net profit	145	688	2,405	2,662	3,171
Adjustments	108	120	0	0	0
Adjusted net profit	253	808	2,405	2,662	3,171

Y/E 31 Mar (Rs mn)	FY20A	FY21A	FY22P	FY23E	FY24E
Accounts payables	1,207	1,297	1,378	2,313	2,589
Other current liabilities	1,036	1,186	879	2,112	2,364
Provisions	120	96	141	184	205
Debt funds	5,611	4,469	2,826	1,712	532
Other liabilities	69	202	682	682	1,226
Equity capital	123	123	123	123	123
Reserves & surplus	6,494	7,181	9,394	11,251	13,463
Shareholders' fund	6,616	7,304	9,516	11,373	13,585
Total liab. and equities	14,658	14,552	15,424	18,376	20,503
Cash and cash eq.	115	720	2,226	2,806	4,707
Accounts receivables	705	778	414	1,458	1,632
Inventories	1,539	1,494	1,658	2,765	3,096
Other current assets	1,131	783	743	1,508	1,689
Investments	0	0	0	0	0
Net fixed assets	11,107	10,741	10,380	9,776	9,315
CWIP	57	36	0	60	61
Intangible assets	4	2	2	2	2
Deferred tax assets, net	0	0	0	0	0
Other assets	0	0	0	0	0
Total assets	14,658	14,552	15,424	18,376	20,503

#### Cash Flows

Y/E 31 Mar (Rs mn)	FY20A	FY21A	FY22P	FY23E	FY24E
Cash flow from operations	720	2,158	3,368	2,890	3,898
Capital expenditures	(242)	(127)	(337)	(210)	(311)
Change in investments	0	0	0	0	0
Other investing cash flows	0	0	481	0	544
Cash flow from investing	(242)	(127)	144	(210)	232
Equities issued/Others	0	0	0	0	0
Debt raised/repaid	(255)	(1,142)	(1,642)	(1,114)	(1,180)
Interest expenses	(302)	(247)	(171)	(180)	(90)
Dividends paid	(44)	(208)	(1,698)	(805)	(959)
Other financing cash flows	(4)	(37)	0	0	0
Cash flow from financing	(605)	(1,634)	(3,512)	(2,100)	(2,229)
Chg in cash & cash eq.	(127)	396	0	580	1,901
Closing cash & cash eq.	72	512	720	2,806	4,707

Y/E 31 Mar (Rs)	FY20A	FY21A	FY22P	FY23E	FY24E
Reported EPS	1.2	5.6	19.6	21.7	25.9
Adjusted EPS	2.1	6.6	19.6	21.7	25.9
Dividend per share	0.3	1.4	4.9	5.4	6.5
Book value per share	54.0	59.6	77.6	92.7	110.8
Valuations Ratios					
Y/E 31 Mar (x)	FY20A	FY21A	FY22P	FY23E	FY24E
EV/Sales	8.3	7.4	4.6	3.9	3.4
EV/EBITDA	50.9	36.4	17.3	15.4	13.2
Adjusted P/E	276.8	86.6	29.1	26.3	22.
P/BV	10.6	9.6	7.4	6.2	5.2
DuPont Analysis Y/E 31 Mar (%)	FY20A	FY21A	FY22P	FY23E	FY24
Tax burden (Net profit/PBT)	216.0	80.0	68.9	70.0	70.
Interest burden (PBT/EBIT)	15.8	72.6	97.7	96.7	100.
EBIT margin (EBIT/Revenue)	8.4	13.6	22.0	21.4	22.
Asset turnover (Rev./Avg TA)	60.0	69.9	108.4	108.6	105.
Leverage (Avg TA/Avg Equity)	2.2	2.1	1.8	1.6	1.
Adjusted ROAE	3.9	11.6	28.6	25.5	25.
Ratio Analysis Y/E 31 Mar	FY20A	FY21A	FY22P	FY23E	FY24
M M (1 (0/)					
YOY growth (%)					
	46.3	16.4	59.2	12.9	12.
Revenue	46.3 84.8	16.4 45.1	59.2 107.2	12.9 8.8	
Revenue EBITDA					13.
Revenue EBITDA Adjusted EPS	84.8	45.1	107.2	8.8	13.
Revenue EBITDA Adjusted EPS Profitability & Return ratios (%)	84.8	45.1	107.2	8.8	13. 19.
Revenue EBITDA Adjusted EPS Profitability & Return ratios (%) EBITDA margin	84.8 11.0	45.1 219.4	107.2 197.6	8.8 10.7	13. 19. 25.
Revenue EBITDA Adjusted EPS <b>Profitability &amp; Return ratios (%)</b> EBITDA margin EBIT margin	84.8 11.0 16.3	45.1 219.4 20.4	107.2 197.6 26.5	8.8 10.7 25.5	13. 19. 25. 22.
Revenue EBITDA Adjusted EPS <b>Profitability &amp; Return ratios (%)</b> EBITDA margin EBIT margin Adjusted profit margin	84.8 11.0 16.3 8.4	45.1 219.4 20.4 13.6	107.2 197.6 26.5 22.0	8.8 10.7 25.5 21.4	13. 19. 25. 22. 15.
Revenue EBITDA Adjusted EPS <b>Profitability &amp; Return ratios (%)</b> EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE	84.8 11.0 16.3 8.4 2.9	45.1 219.4 20.4 13.6 7.9	107.2 197.6 26.5 22.0 14.8	8.8 10.7 25.5 21.4 14.5	13. 19. 25. 22. 15. 25.
Revenue EBITDA Adjusted EPS <b>Profitability &amp; Return ratios (%)</b> EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE	84.8 11.0 16.3 8.4 2.9 3.9	45.1 219.4 20.4 13.6 7.9 11.6	107.2 197.6 26.5 22.0 14.8 28.6	8.8 10.7 25.5 21.4 14.5 25.5	13. 19. 25. 22. 15. 25.
Revenue EBITDA Adjusted EPS <b>Profitability &amp; Return ratios (%)</b> EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE	84.8 11.0 16.3 8.4 2.9 3.9	45.1 219.4 20.4 13.6 7.9 11.6	107.2 197.6 26.5 22.0 14.8 28.6	8.8 10.7 25.5 21.4 14.5 25.5	13 19. 25 22. 15. 25. 23.
Revenue EBITDA Adjusted EPS <b>Profitability &amp; Return ratios (%)</b> EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE <b>Working capital days (days)</b> Receivables	84.8 11.0 16.3 8.4 2.9 3.9 6.0	45.1 219.4 20.4 13.6 7.9 11.6 7.9	107.2 197.6 26.5 22.0 14.8 28.6 20.4	8.8 10.7 25.5 21.4 14.5 25.5 21.6	13 19. 25 22. 15. 25 23 23
Revenue EBITDA Adjusted EPS <b>Profitability &amp; Return ratios (%)</b> EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE <b>Working capital days (days)</b> Receivables Inventory	84.8 11.0 16.3 8.4 2.9 3.9 6.0 24	45.1 219.4 20.4 13.6 7.9 11.6 7.9 27	107.2 197.6 26.5 22.0 14.8 28.6 20.4 13	8.8 10.7 25.5 21.4 14.5 25.5 21.6 19	13. 19. 25. 22. 15. 25. 23. 23. 22. 23.
Revenue EBITDA Adjusted EPS <b>Profitability &amp; Return ratios (%)</b> EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE <b>Working capital days (days)</b> Receivables Inventory Payables	84.8 11.0 16.3 8.4 2.9 3.9 6.0 24 134	45.1 219.4 20.4 13.6 7.9 11.6 7.9 27 27 120	107.2 197.6 26.5 22.0 14.8 28.6 20.4 13 86	8.8 10.7 25.5 21.4 14.5 25.5 21.6 19 102	13. 19. 25. 22. 15. 25. 23. 23. 22. 23.
Revenue EBITDA Adjusted EPS <b>Profitability &amp; Return ratios (%)</b> EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE <b>Working capital days (days)</b> Receivables Inventory Payables	84.8 11.0 16.3 8.4 2.9 3.9 6.0 24 134	45.1 219.4 20.4 13.6 7.9 11.6 7.9 27 27 120	107.2 197.6 26.5 22.0 14.8 28.6 20.4 13 86	8.8 10.7 25.5 21.4 14.5 25.5 21.6 19 102	13. 19. 25. 22. 15. 25. 23. 23. 22. 12 5
Revenue EBITDA Adjusted EPS <b>Profitability &amp; Return ratios (%)</b> EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE <b>Working capital days (days)</b> Receivables Inventory Payables <b>Ratios (x)</b> Gross asset turnover	84.8 11.0 16.3 8.4 2.9 3.9 6.0 24 134 50	45.1 219.4 20.4 13.6 7.9 11.6 7.9 27 120 56	107.2 197.6 26.5 22.0 14.8 28.6 20.4 13 86 41	8.8 10.7 25.5 21.4 14.5 25.5 21.6 19 102 49	13.1 19. 25.1 22. 15. 25. 23. 23. 21 2 51 51 51 51 51 51
Inventory Payables Ratios (x)	84.8 11.0 16.3 8.4 2.9 3.9 6.0 24 134 50 0.6	45.1 219.4 20.4 13.6 7.9 11.6 7.9 27 120 56 0.7	107.2 197.6 26.5 22.0 14.8 28.6 20.4 13 86 41	8.8 10.7 25.5 21.4 14.5 25.5 21.6 19 102 49 1.2	12. 13. 19. 25. 22. 15. 25. 23. 22. 12. 5. 23. 1. 25. 5. 23. 20. 12. 5. 5. 25. 25. 25. 25. 25. 25.

 Adjusted debt/equity
 0.8
 0.5

 Source: Company, BOBCAPS Research | Note: TA = Total Assets



# Disclaimer

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%


HOLD - Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

#### Ratings and Target Price (3-year history): GREENPANEL INDUSTRIES (GREENP IN)



B - Buy, H - Hold, S - Sell, A - Add, R - Reduce

#### Rating distribution

As of 30 April 2022, out of 116 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 66 have BUY ratings, 30 have HOLD ratings, 5 are rated ADD\*, 1 is rated REDUCE\* and 14 are rated SELL. One company rated ADD has been an investment banking client in the last 12 months. (\*Our ADD and REDUCE ratings are in the process of being migrated to the new recommendation structure.)

#### Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

#### General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017. BOBCAPS CIN Number: U65999MH1996GOI098009.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

### **GREENPANEL INDUSTRIES**



This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities —that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company in the past 12 months. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.